Endo International Given FDA Approval For Micafungin New Formulation
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212156
Atea Pharmaceuticals Shares Spike Higher After The New York Times Reports U.S. Considering Back Co’s COVID Drugs
https://www.nytimes.com/2021/06/17/health/covid-pill-antiviral.html
Amneal’s Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer
The FDA has accepted for review Amneal Pharmaceuticals Inc’s (NYSE:AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway of…
Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer
The FDA has accepted for review Agenus Inc’s (NASDAQ:AGEN) marketing application seeking approval for balstilimab for recurrent or metastatic cervical cancer…
Turning Point Therapeutics Reports Was Granted FDA Orphan Drug Designation For TPX-0022 In Gastric Cancer
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that TPX-0022, the company’s inhibitor of MET
Onconova Therapeutics Announces Peer-Reviewed Publication Of Preclinical Data Demonstrating Synergistic Anti-Cancer Activity Of Rigosertib Combined With Immune Checkpoint Blockade
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication
Nanox Announces FDA 510(k) Submission for First Version of Multi-Source Nanox.ARC
NANOX IMAGING LTD (NASDAQ:NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that the Company has submitted a 510(k) premarket notification
Applied Therapeutics Stock Moves Higher On FDA Fast Track Review For AT-007 In Rare Metabolic Disorder
The FDA has granted Fast Track designation to Applied Therapeutics Inc’s (NASDAQ:APLT) AT-007 to treat Galactosemia, a rare metabolic disease. AT-007 is…
Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia
Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today